09:14 AM EDT, 05/06/2024 (MT Newswires) -- BioAtla ( BCAB ) said Monday its investigational new drug application to assess BA3361 antibody drug conjugate to treat multiple tumor types has been cleared by the US Food and Drug Administration.

The CAB technology is developed to treat both on-target, off-tumor and off-target, off-tumor toxicities, the company said.

Shares of the company were up 3.1% in Monday premarket activity.

Price: 3.3500, Change: +0.10, Percent Change: +3.08